In a report released yesterday, Elliot Wilbur from Raymond James maintained a Hold rating on Aerie Pharma (AERI). The company’s shares closed last Friday at $11.67, close to its 52-week low of $10.22.
According to TipRanks.com, Wilbur has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -3.7% and a 40.7% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Sol-Gel Technologies, and ANI Pharmaceuticals.
Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $27.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.26 and a one-year low of $10.22. Currently, Aerie Pharma has an average volume of 761.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
